GlassScriptPhysician profile
Robert S Grodman
NPI 1164495313
$14,545.34
in general payments reported to CMS, 2019-2025
47 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,847 · 2020: $1,021 · 2021: $1,601 · 2022: $1,446 · 2023: $1,825 · 2024: $4,112 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,497 · Travel and Lodging: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,497.45 |
| Travel and Lodging | $1,133.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,637.52 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $1,928.35 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Gallant |
| Janssen Pharmaceuticals, INC | $1,630.96 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $695.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $590.26 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $576.29 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $526.35 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $424.11 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $415.16 | 2019-2025 | |
| Novo Nordisk INC | $325.95 | 2024-2025 | Wegovy, Ozempic |
| Philips North America LLC | $310.75 | 2020-2025 | (Ck4) Mcot, Ecc Solutions, (5044) Mcot |
| Amgen INC. | $285.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.47 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $244.60 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $187.34 | 2023-2025 | Amvuttra, Onpattro |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $184.44 | 2019-2023 | |
| Lilly USA, LLC | $172.15 | 2023-2024 | Mounjaro, Trulicity |
| Tactile Systems Technology INC | $169.44 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Esperion Therapeutics, INC. | $160.72 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $143.92 | 2019-2024 | |
| Heartflow, INC. | $142.39 | 2023-2025 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $140.77 | 2019-2021 | |
| Edwards Lifesciences Corporation | $139.85 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $138.85 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $113.86 | 2024 | Assure Wcd |
| Medtronic, INC. | $110.52 | 2022-2025 | Corevalve Evolut R |
| Regeneron Healthcare Solutions, INC. | $103.97 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $102.59 | 2022-2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $101.59 | 2022-2025 | Opsumit, Uptravi |
| Lundbeck LLC | $83.49 | 2019-2020 | |
| Abiomed | $74.23 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $50.11 | 2024 | Arcalyst |
| Baxter Healthcare | $47.46 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Bridgebio Pharma, INC. | $47.36 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $45.17 | 2023-2024 | Inpefa |
| Chiesi USA, INC. | $39.68 | 2024-2025 | Juxtapid |
| Cordis US Corp. | $38.41 | 2025 | Mynx Control Venous, Mynxgrip |
| Amryt Pharma Holdings LTD | $31.87 | 2020-2021 | |
| Bardy Diagnostics, INC. | $23.96 | 2020-2021 | |
| Akcea Therapeutics, INC. | $22.30 | 2020 | |
| Angiodynamics, INC. | $20.76 | 2021 | |
| Astellas Pharma US INC | $17.75 | 2019 | |
| Medtronic Vascular, INC. | $15.76 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $15.14 | 2024 | Rhythm Express |
| Medicomp INC | $13.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.